IFG
CRSP icon

Independent Financial Group’s CRISPR Therapeutics CRSP Stock Holding History

Independent Financial Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$331K Sell
6,062
-784
-11% -$41.3K 0.01% 1192
2026
Q1 		$326K Sell
6,846
-650
-9% -$34.3K 0.01% 1118
2025
Q4 		$393K Buy
7,496
+2,497
+50% +$150K 0.01% 1016
2025
Q3 		$324K Buy
4,999
+463
+10% +$26.6K 0.01% 1054
2025
Q2 		$221K Buy
+4,536
New +$176K 0.01% 1181
2024
Q4 		– Sell
-5,338
Closed -$251K – 1175
2024
Q3 		$251K Sell
5,338
-1,628
-23% -$82.6K 0.01% 951
2024
Q2 		$376K Buy
6,966
+1,705
+32% +$98.6K 0.02% 732
2024
Q1 		$359K Buy
+5,261
New +$377K 0.02% 710
2021
Q3 		– Sell
-2,495
Closed -$404K – 717
2021
Q2 		$404K Buy
2,495
+581
+30% +$70.7K 0.04% 434
2021
Q1 		$233K Sell
1,914
-88
-4% -$13.3K 0.03% 542
2020
Q4 		$307K Buy
+2,002
New +$237K 0.05% 419

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Independent Financial Group's CRSP Position: Q2 2026 in Review

Independent Financial Group reduced its CRISPR Therapeutics (CRSP) stake by 11% in Q2 2026, selling an estimated $41.3K and leaving 6,062 shares worth $331K. The position accounts for 0.01% of the portfolio, ranked #1192.

Independent Financial Group first reported a position in CRSP in Q4 2020 and has held it in 11 quarters since. The position peaked at $404K in Q2 2021. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Independent Financial Group held 6,062 shares of CRISPR Therapeutics worth $331K as of Q2 2026.
  • Independent Financial Group sold 784 CRISPR Therapeutics shares in Q2 2026, an estimated $41.3K.
  • CRISPR Therapeutics made up 0.01% of Independent Financial Group's portfolio in Q2 2026, its #1192 holding.
  • Independent Financial Group first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 11 quarters since.
  • Independent Financial Group's CRISPR Therapeutics position peaked at $404K in Q2 2021.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Independent Financial Group's 13F filing for Q2 2026, filed 15 Jul 2026.